Sources

8 Total Sources

Daraxonrasib Reaches Metastatic Pancreatic Cancer Patients, Extending Median Survival to 13 Months

The Star Online1d ago

Experimental Drug Daraxonrasib Offers Hope to Metastatic Pancreatic Cancer Patients

New York Post 1d ago

New pancreatic cancer drug nearly doubles life expectancy

Yahoo! Voices1d ago

New Pancreatic Cancer Drug Daraxonrasib Reaches Patients, Doubling Survival

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | New England Journal of Medicine

The Post and Courier1d ago

New pancreatic cancer drug finally reaches Charleston

RASolute 302 Trial Shows Survival Benefit in Pancreatic Cancer | Revolution Medicines posted on the topic | LinkedIn

Instagram1d ago

RASolute 302 trial results were hailed as a game-changing breakthrough in the treatment of pancreatic cancer. In the primary endpoint population of patients with RAS G12 mutations, median OS reached 13.2 months

Exclusive: Biggest Pancreatic Cancer Breakthrough In 50 Years, Says Indian Doctor, Co-Author Of Global Clinical Trial